Skip to main content
SpringerLink
Log in

Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections

  • Article
  • Published:
European Journal of Clinical Microbiology and Infectious Diseases Aims and scope Submit manuscript

Abstract

In an open, controlled, randomized study the safety and efficacy of imipenem/cilastatin was compared with that of the combination cefotaxime/gentamicin (plus metronidazole in patients with suspected anaerobe infection) in the treatment of 337 patients from 12 German and 5 Austrian centers who had non-life-threatening infections. The evaluation was done on an intention-to-treat basis (i.e. all patients including protocol violators) and according to the protocol (144 patients in the imipenem/cilastatin group and 124 in the cefotaxime/gentamicin group). No significant differences were seen between the two treatment groups in terms of the clinical and bacteriological outcome. The frequency of infusion intolerance and thrombophlebitis was low in both groups (< 2 %). The overall rate of adverse events was comparable in the two groups, nausea, vomiting and diarrhea being the most frequent events. Nephrotoxicity, indicated by an increase in serum creatinine, was significantly higher in the cefotaxime/gentamicin group. Imipenem/cilastatin was shown to be as effective as cefotaxime/gentamicin (metronidazole) and appears to be well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

We’re sorry, something doesn't seem to be working properly.

Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Similar content being viewed by others

References

  1. Braveny I In vitro activity of imipenem — a review. European Journal of Clinical Microbiology 1984, 3: 456–462.

    PubMed  Google Scholar 

  2. Tally FP, Jacobus NV, Gorbach SL In vitro activity of N-formimidoyl thienamycin (MK0787). Antimicrobial Agents and Chemotherapy 1980, 18: 642–644.

    PubMed  Google Scholar 

  3. Blumental RM, Raeder R, Takemoto CD, Earl Freimer H Occurrence and expression of imipenem (M-formimdoyl thienamycin) resistance in clinical isolates of coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 1983, 24: 61–69.

    PubMed  Google Scholar 

  4. Kropp H, Gerckens L, Sundelof JG, Kahan FM Antibacterial activity of imipenem: the first thienamycin antibiotic. Reviews of Infectious Diseases 1985, 7: 389–410.

    Google Scholar 

  5. Norrby SR, Alestig K, Ferber F, Huber JL, Jones KH, Kahn FM, Meisinger MAP, Rogers JD Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans. Antimicrobial Agents and Chemotherapy 1983, 23: 293–299.

    PubMed  Google Scholar 

  6. Norrby SR, Alestig K, Björnegard B Urinary recovery of N-formimidoyl thienamycin (MK0787) as affected by coadministration of N-formimidoyl thienamycin dehydropeptidase inhibitors. Antimicrobial Agents and Chemotherapy 1983, 23: 300–307.

    PubMed  Google Scholar 

  7. The Scandinavian Study Group Imipenem/cilastatin versus gentamycin/clindamycin for treatment of serious bacterial infections. Lancet 1984, i: 868–871.

    Google Scholar 

  8. Danziger LH, Creger RJ, Shwed JA, Stellato TA, Hau T Randomized trial of imipenem-cilastatin versus gentamicin plus clindamycin in the treatment of polymicrobial infections. Pharmacotherapy 1988, 8: 315–318.

    PubMed  Google Scholar 

  9. Solomkin JS, Fant WK, Rivera JO, Alexander JW Randomized trial of imipenem/cilastatin versus gentamicin and cilastatin in mixed flora infections. American Journal of Medicine 1985, 78, Supplement 5A: 85–89.

    Article  PubMed  Google Scholar 

  10. Bauer AW, Kirby WMM, Sherris JC, Turck M Antibiotic susceptibility testing by a standardized single disk method. American Journal of Clinical Pathology 1966, 45: 493–496.

    PubMed  Google Scholar 

  11. Lietman PS, Smith CR Aminoglycoside nephrotoxicity in humans. Reviews of Infectious Diseases 1983, 5, Supplement 2: 284–292.

    Google Scholar 

  12. Potgieter PD, Linton DM, Forder AA, Plumb H Imipenem/cilastatin in the treatment of severe nosocomial pneumonia. South American Medical Journal 1988, 74: 390–392.

    Google Scholar 

  13. Wathen CG, Carbarns NJ, Jones PA, Millar A, Croughan MJ, Calder MA, Douglas NJ Imipenemcilastatin in the treatment of respiratory infections in patients with chronic airways obstructions. Journal of Antimicrobial Chemotherapy 1988, 21: 107–112.

    Google Scholar 

  14. Sweet RL Imipenem/cilastatin in the treatment of obstetric and gynecologic infections: a review of worldwide experience. Reviews of Infectious Diseases 1985, 7: 522–527.

    Google Scholar 

  15. Kager L, Nord CE Imipenem/cilastatin in the treatment of intra-abdominal infections: a review of worldwide experience. Reviews of Infectious Diseases 1985, 7: 518–521.

    Google Scholar 

  16. Norwegian Study Group Imipenem/cilastatin as monotherapy in severe infections: Comparison with cefotaxime in combination with metronidazole and cloxacillin. Scandinavian Journal of Infectious Diseases 1987, 19: 667–675.

    Google Scholar 

  17. Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, Andrien F, Baudrihaye M, Bow E, Burman LA, Bury J, Ezzedine H, Gigi J, Granlund M, Holm J, Lundberg S, Michaux JL, Le Saux N, Wahlin A, Zakrisson E Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multiclinic study. Scandinavian Journal of Infectious Diseases 1987, Supplement 52: 65–78.

    Google Scholar 

  18. Nielsen DM, Katz JR, Ahloy RD, Hansen RS, Meyer RD Imipenem/cilastatin therapy for serious bacterial infections. Reviews of Infectious Diseases 1985, 7, Supplement 3: 506–512.

    Google Scholar 

  19. Brooks RG, McCabe RE, Vosti KL, Remington JS Open trial of imipenem/cilastatin therapy for serious bacterial infections. Reviews of Infectious Diseases 1985, 7, Supplement 3: 496–505.

    Google Scholar 

  20. Chiodini PL, Geddes AM, Smith EG, Conlon CP, Farrell ID Imipenem/cilastatin in the treatment of serious bacterial infections. Reviews of Infectious Diseases 1985, 7, Supplement 3: 490–495.

    Google Scholar 

  21. Broze B, De Mees J, Droissart R, Nolens VP, Staudt JP, Verstraeten ME, de Lame PA Randomized comparison of imipenem/cilastatin and ceftazidime in the empiric therapy of severe abdominal infections: a multicenter study. Acta Clinica Belgica 1987, 42: 431–436.

    PubMed  Google Scholar 

  22. Wang C, Calandra GB, Azis MA, Brown KR Efficacy and safety of imipenem/cilastatin: a review of worldwide clinical experience. Reviews of Infectious Diseases 1985, 7, Supplement 3: 528–536.

    Google Scholar 

  23. Calandra GB, Lydick E, Carrigan J Factors predisposing to seizures in seriously ill infected patients receiving antibiotics: experience with imipenem/cilastatin. American Journal of Medicine 1988, 84: 911–918.

    Article  PubMed  Google Scholar 

  24. Eisenberg JM, Koffer H, Glick HA, Connell ML, Loss LE, Talbot GH, Shustermann NH, Strom BL What is the cost of nephrotoxicity associated with aminoglycosides? Annals of Internal Medicine 1987, 107: 900–909.

    PubMed  Google Scholar 

Download references

Author information

Consortia

German and Austrian Imipenem/Cilastatin Study Group

Additional information

Responsible Member of the Study Group: W. Stille, Zentrum der Inneren Medizin, Klinikum der Johann-Wolfgang-Goethe-Universität, Theodor-Stern-Kai 7, 6000 Frankfurt 70, Germany.

Members of the Study Group:Chairman: W. Stille, Frankfurt.Clinical Coordinator: P.M. Shah, Frankfurt.Microbiological Coordinator: U. Ullmann, Kiel.Company Monitors: B. Hoffstedt & C. Kreisl, MSD, Munich.Investigators: B. Bommersbach & K. Rauscher, Memmingen; G. Görtz, C. Germer & K. Hager, Berlin; P. Kujath & I. Ebert, Würzburg; N. Laessing, Kiel; H. Meffert, Koblenz; N. Neubauer & E. Heger, Langen; G. Rohr, Mannheim; H. Wacha, Frankfurt; I.M. Wittke, Kiel; H. Wolf, Hamburg; V. Zumtobel & C. Wiemer, Bochum; K. Dinstl, Wien; W. Graninger & E. Presterl, Wien; N. Hölbling, Salzburg; C. Menzel, Salzburg; W. Schulz, Wien.Microbiologists: H. Grimm, Weingarten; H. Hahn, Berlin; N. Hof, Mannheim; W. Opferkuch, Bochum; A. Georgopoulos, Wien.Statistician: D. Chase, Munich.

Rights and permissions

Reprints and permissions

About this article

Cite this article

German and Austrian Imipenem/Cilastatin Study Group. Randomized multicenter clinical trial with imipenem/cilastatin versus cefotaxime/gentamicin in the treatment of patients with non-life-threatening infections. Eur. J. Clin. Microbiol. Infect. Dis. 11, 683–692 (1992). https://doi.org/10.1007/BF01989971

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01989971

Keywords

Search

Navigation